Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

By Yahoo! Finance | Nov 13, 2024 at 02:31 AM EST

The 40% increase in hospital doses and market share for Yupelri is driven by formulary approvals and therapeutic interchange protocols. Efforts to expand these strategies aim to sustain growth. A strategic review committee seeks to unlock value for shareholders, with ASP improvements expected in early 2025.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.